KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aurinia Pharmaceuticals (AUPH) Receivables: 2018-2024

Historic Receivables for Aurinia Pharmaceuticals (AUPH) over the last 7 years, with Dec 2024 value amounting to $36.5 million.

  • Aurinia Pharmaceuticals' Receivables fell 15.81% to $30.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $147.7 million, marking a year-over-year increase of 28.42%. This contributed to the annual value of $36.5 million for FY2024, which is 51.70% up from last year.
  • According to the latest figures from FY2024, Aurinia Pharmaceuticals' Receivables is $36.5 million, which was up 51.70% from $24.1 million recorded in FY2023.
  • Over the past 5 years, Aurinia Pharmaceuticals' Receivables peaked at $36.5 million during FY2024, and registered a low of $13.5 million during FY2022.
  • For the 3-year period, Aurinia Pharmaceuticals' Receivables averaged around $24.7 million, with its median value being $24.1 million (2023).
  • As far as peak fluctuations go, Aurinia Pharmaceuticals' Receivables fell by 12.42% in 2022, and later soared by 78.44% in 2023.
  • Yearly analysis of 4 years shows Aurinia Pharmaceuticals' Receivables stood at $15.4 million in 2021, then fell by 12.42% to $13.5 million in 2022, then spiked by 78.44% to $24.1 million in 2023, then spiked by 51.70% to $36.5 million in 2024.